Efficacy and Safety of Low-Dose Versus Standard-Dose Valganciclovir for Prevention of Cytomegalovirus Disease in Intermediate-Risk Kidney Transplant Recipients.
Experimental and Clinical Transplantation2016Vol. 14(5), pp. 526–534
Citations Over Time
Medhat A Halim, Torki Al-Otaibi, Osama Gheith, Hani Adel, Ahmed Mosaad, Abu-Atteya Hasaneen, Zakaria Zakaria, Yahya Makkeya, Tarek Said, Prasad Nair
Abstract
Six months of low-dose valganciclovir prophylaxis for intermediate-risk kidney transplant recipients was as effective as high-dose valganciclovir with a better safety profile.
Related Papers
- → Oral Valganciclovir Is Noninferior to Intravenous Ganciclovir for the Treatment of Cytomegalovirus Disease in Solid Organ Transplant Recipients(2007)423 cited
- → Oral valganciclovir as pre-emptive therapy has similar efficacy on cytomegalovirus DNA load reduction as intravenous ganciclovir in allogeneic stem cell transplantation recipients(2006)65 cited
- → Use of High-Dose Ganciclovir for the Treatment of Cytomegalovirus Replication in Solid Organ Transplant Patients With Ganciclovir Resistance-Inducing Mutations(2013)54 cited
- → Cytomegalovirus infection in high‐risk kidney transplant recipients receiving thymoglobulin induction—a single‐center experience(2016)11 cited
- [Valganciclovir. Oral treatment of Cytomegalovirus infections].(2004)